From tech transfer to commercialization: The formulas that guided Bruin Biometrics

Back in 2012, Martin Burns spotted a UCLA-born device prototype in a magazine, a novel technology designed to detect pressure injuries, commonly known as bedsores, before they happen. Thirteen years later, the former strategy consultant and now Chief Executive Officer of Bruin Biometrics has spent the past decade turning the company and that technology into a global player in wound-care technology.

In an interview with Medical Device and Technology, Burns traces how that moment led to Bruin’s signature product: the Provizio SEM Scanner, a handheld device that uses capacitance to quantify sub-epidermal moisture and flag the risk of bedsores. The device can do this days before skin breaks down, regardless of a patient’s skin tone.

In this segment, Burns discusses the "formulas" that guided Bruin Biometrics through the challenges of bringing a device to market.

About Martin Burns

Appointed CEO of Bruin Biometrics in 2012, Martin Burns designed and led the successful journey of Bruin Biometrics’ SEM Scanner through the company’s concept-to-commercialization “formulas strategy.” Significant milestones include FDA de novo Marketing Authorization (2018), CE Marking (2013) and in 2020 he negotiated a global distribution arrangement and investment with Arjo. Martins’ background is strategy and operations management consulting to large med tech companies. He earned his MBA from UCLA’s Anderson School of Management, where he is a guest speaker on healthcare strategy and medical device marketing courses, and his BA from the London School of Economics.